Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.

Subsidie
€ 1.500.000
2025

Projectdetails

Introduction

Amid the antibiotic resistance crisis, the century-old practice of phage therapy, the use of bacterial viruses to treat bacterial infections, has gained renewed attention. Despite extensive research and clear-cut advantages over antibiotics, phage therapy has yet to gain momentum. This is primarily due to remaining limitations, e.g., the time-consuming process of identifying suitable phages and limited in vivo efficacy.

Proposed Technology

With PHAGE-PRO, I propose a new technology to overcome the shortcomings of traditional phage therapy. Unlike the conventional use of lytic phages, I will capitalize on prophages – viruses that integrate into bacterial genomes capable of excision and replication.

Benefits of Prophages

By integrating prophages into safe carrier strains, originating from probiotics, I will unlock two pivotal benefits:

  1. Rapid identification of suitable phages using advanced machine learning.
  2. Sustained in-vivo efficacy.

Yet, the core advantage of PHAGE-PRO lies in its unparalleled synergy of phage killing and pathogen competitive exclusion imposed by the probiotic.

Development Process

To realize this concept, the development of predictive tools is essential to quickly identify the most promising prophages and probiotic combinations for each pathogen (WP1).

Prophage Engineering

Prophage engineering (WP2), followed by rigorous in vitro testing, will ensure high safety and efficacy. High-throughput in vivo experiments using wax moth larvae will reveal the most promising candidate, which I will subsequently validate through a proof of principle experiment using a poultry model (WP3).

Broader Impact

Although I initially tailored PHAGE-PRO to treat Salmonella infections in poultry, its impact extends far beyond. This new technology holds the potential for transformative changes in phage therapy, not only advancing infection management in livestock farming through the enhancement of animal health and the assurance of food product safety, but also by opening the door for targeted preventive and therapeutic interventions in human medicine.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.500.000
Totale projectbegroting€ 1.500.000

Tijdlijn

Startdatum1-1-2025
Einddatum31-12-2029
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENpenvoerder
  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phages

This project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions.

€ 1.499.250
ERC Consolid...

Phage infection of bacterial biofilm

This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.

€ 1.992.976
ERC Consolid...

In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR

This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.

€ 1.999.780
ERC Advanced...

Breaking resistance of pathogenic bacteria by chemical dysregulation

The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.

€ 2.499.785
ERC Starting...

Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs

This project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies.

€ 1.496.500

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

in silico bio-evolutio - novel AI paradigm for molecular biology

This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.

€ 1.692.596
EIC Accelerator

Fast, easy diagnostics for personalised phage therapy

Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.

€ 1.800.000
Mkb-innovati...

InnomABs

IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.

€ 14.888
EIC Pathfinder

Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections

LeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations.

€ 2.665.564
EIC Pathfinder

Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance

MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.

€ 3.194.450